Literature DB >> 16757416

Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.

Xavier Thomas, Arnaud Pigneux, Emmanuel Raffoux, Francoise Huguet, Denis Caillot, Pierre Fenaux.   

Abstract

There is still no consensus on the best approach for the treatment of relapsing acute promyelocytic leukemia. All-trans retinoic acid plus chemotherapy is hampered by potential mechanisms of resistance, and the safety profile of chemotherapy may be considered as not acceptable before stem cell transplantation. Arsenic trioxide provides an option for these patients.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16757416

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  8 in total

1.  Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet.

Authors:  E Lengfelder; F Lo-Coco; L Ades; P Montesinos; D Grimwade; B Kishore; S M Ramadan; M Pagoni; M Breccia; A J G Huerta; A M Nloga; J D González-Sanmiguel; A Schmidt; J-F Lambert; S Lehmann; E Di Bona; B Cassinat; W-K Hofmann; D Görlich; M-C Sauerland; P Fenaux; M Sanz
Journal:  Leukemia       Date:  2015-01-28       Impact factor: 11.528

2.  Treatment of acute promyelocytic leukemia for older patients.

Authors:  Thomas Prebet; Steven D Gore
Journal:  J Natl Compr Canc Netw       Date:  2011-03       Impact factor: 11.908

3.  The anti-leukemic effect of carnosic acid combined with adriamycin in a K562/A02/SCID leukemia mouse model.

Authors:  Lu-Qun Wang; Ran Wang; Xiang-Xin Li; Xiao-Ning Yu; Xue-Liang Chen; Hao Li
Journal:  Int J Clin Exp Med       Date:  2015-07-15

4.  Role of arsenic trioxide in acute promyelocytic leukemia.

Authors:  Harry J Iland; John F Seymour
Journal:  Curr Treat Options Oncol       Date:  2013-06

Review 5.  Current first- and second-line treatment options in acute promyelocytic leukemia.

Authors:  Fulvio Massaro; Matteo Molica; Massimo Breccia
Journal:  Int J Hematol Oncol       Date:  2017-02-02

Review 6.  Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives.

Authors:  Derek McCulloch; Christina Brown; Harry Iland
Journal:  Onco Targets Ther       Date:  2017-03-14       Impact factor: 4.147

7.  Development of a risk grading system to identify patients with acute promyelocytic leukemia at high risk of early death.

Authors:  Yingmei Zhang; Wenyi Hou; Ping Wang; Jinxiao Hou; Hongli Zhao; Bo Jin; Jiayue Sun; Fenglin Cao; Yanqiu Zhao; Haitao Li; Fei Ge; Jinyue Fu; Jin Zhou
Journal:  Cancer Manag Res       Date:  2018-09-17       Impact factor: 3.989

Review 8.  Management of elderly patients with acute promyelocytic leukemia: progress and problems.

Authors:  Eva Lengfelder; Wolf-Karsten Hofmann; Florian Nolte
Journal:  Ann Hematol       Date:  2013-05-22       Impact factor: 3.673
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.